A Study of PN20 in Healthy Adult Volunteers

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 16, 2022

Primary Completion Date

January 5, 2023

Study Completion Date

January 5, 2023

Conditions

Chemotherapy-induced ThrombocytopeniaImmune Thrombocytopenic Purpura

Interventions

DRUG

PN20

Six dose levels of PN20 will be evaluated

DRUG

Placebo

Placebo of PN20

Trial Locations (1)

The First Affiliated Hospital of Soochow University, Suzhou

All Listed Sponsors

lead

Chongqing Peg-Bio Biopharm Co., Ltd.

INDUSTRY